Catalyst Oncology

Graceway Pharmaceuticals obtained commercialization rights to three dermatological molecules from Pfizer. The acquisition and license agreement includes related transferred or licensed intellectual properties. This transaction is part of Pfizer’s plan to out-license noncore programs; the firm identified CNS diseases, oncology, and cardiovascular diseases as its focus. Pfizer continues to be responsible, however, for performing developmental and clinical services for these three molecules.

Go here to read the rest:
Graceway Acquires Dermatological Compounds from Pfizer